AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35705150 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid intake
Number of subjects: 0
Study 35705150 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction (1500ml/day)
Number of subjects: 0
Study 33582490 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐FiTT distress‐induction task (high difficulty)
Number of subjects: 484
Study 33582490 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐FiTT distress‐induction task (low difficulty)
Number of subjects: 484
Study 33582490 — intervention group
Group type: COMPARATOR
Intervention: Neutral control group
Number of subjects: 484
Study 33582490 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐FiTT distress‐induction task (neutral cues)
Number of subjects: 484
Study 33582490 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐FiTT distress‐induction task (withdrawal cues)
Number of subjects: 484
Study 32275367 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (electroacupuncture at specified acupoints, continuous wave, 2 Hz, 30 min, 3 times a week for 1 month, 4 courses total)
Number of subjects: 40
Study 32275367 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle interventions (exercise and diet guidance)
Number of subjects: 40
Study 32275367 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 40
Study 35523242 — intervention group
Group type: EXPERIMENTAL
Intervention: IMB model intervention group (n = 30)
Number of subjects: 60
Study 35523242 — intervention group
Group type: COMPARATOR
Intervention: Standard OAB management control group (n = 30)
Number of subjects: 60
Study 32941794 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy plus surgery
Number of subjects: 266
Study 32941794 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 266
Study 33245796 — intervention group
Group type: COMPARATOR
Intervention: Evogliptin (5 mg single dose) in patients with mild hepatic impairment
Number of subjects: 0
Study 33245796 — intervention group
Group type: COMPARATOR
Intervention: Evogliptin (5 mg single dose) in patients with moderate hepatic impairment
Number of subjects: 0
Study 33245796 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin (5 mg single dose)
Number of subjects: 0
Study 32714084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent repeated doses of dexamethasone (15 mg total)
Number of subjects: 42
Study 32714084 — intervention group
Group type: COMPARATOR
Intervention: One-time 5-mg dose of dexamethasone
Number of subjects: 42
Study 35941548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal injection of Magnesium sulphate with steroids
Number of subjects: 135
Study 35941548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal injection of Ozone with steroids
Number of subjects: 135
Study 35941548 — intervention group
Group type: COMPARATOR
Intervention: Steroids alone
Number of subjects: 135
Study 33632940 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 49
Study 33632940 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 49
Study 33226116 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse probability of treatment weights (IPTWs)
Number of subjects: 0
Study 33226116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size calculations with design effects
Number of subjects: 0
Study 32463163 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal bridging
Number of subjects: 50
Study 32463163 — intervention group
Group type: COMPARATOR
Intervention: Conventional fascial closure
Number of subjects: 50
Study 33768522 — intervention group
Group type: EXPERIMENTAL
Intervention: Banafine®
Number of subjects: 30
Study 32118788 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious thermal stimulation (TS) at temperatures 46°C to 47°C (hot pain) and 7°C to 8°C (cold pain)
Number of subjects: 16
Study 32118788 — intervention group
Group type: COMPARATOR
Intervention: Innocuous thermal stimulation (TS) at temperatures 40°C to 41°C (hot) and 20°C to 21°C (cold)
Number of subjects: 16
Study 35513022 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 120
Study 35513022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33863842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care (NLC)
Number of subjects: 224
Study 33863842 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologist-led care (RLC)
Number of subjects: 224
Study 34799440 — intervention group
Group type: EXPERIMENTAL
Intervention: NHANES-III equation with 'North Indian and Pakistani' conversion factor
Number of subjects: 1724
Study 34799440 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Lung Function Initiative (GLI) equation for 'other or mixed ethnicities'
Number of subjects: 1724
Study 34799440 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent equation derived from a western Indian population
Number of subjects: 1724
Study 34799440 — intervention group
Group type: EXPERIMENTAL
Intervention: Older and smaller survey of Karachi residents
Number of subjects: 1724
Study 34799440 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1/FVC ratio (<lower limit of normality)
Number of subjects: 1724
Study 33960667 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone dressings (a contact layer and/or foam)
Number of subjects: 126
Study 33960667 — intervention group
Group type: COMPARATOR
Intervention: Non-adhesive dressings
Number of subjects: 126
Study 33653634 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy (RARC) after previous prostate surgery (PPS)
Number of subjects: 220
Study 70648026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg q12h
Number of subjects: 797
Study 70648026 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin/aztreonam (V/A) 1 g/1 g q12h
Number of subjects: 797
Study 33264236 — intervention group
Group type: EXPERIMENTAL
Intervention: LED flashlights in Risk Group 2
Number of subjects: 6
Study 33264236 — intervention group
Group type: EXPERIMENTAL
Intervention: LED flashlights in Risk Group 1
Number of subjects: 6
Study 33264236 — intervention group
Group type: EXPERIMENTAL
Intervention: All evaluated flashlights
Number of subjects: 6
Study 32023373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower threshold treatment (glucose concentration <36 mg/dL)
Number of subjects: 689
Study 32023373 — intervention group
Group type: COMPARATOR
Intervention: Traditional threshold treatment (glucose concentration <47 mg/dL)
Number of subjects: 689
Study 616841087 — intervention group
Group type: COMPARATOR
Intervention: 0 g fiber from SCF/d
Number of subjects: 0
Study 616841087 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g fiber from SCF/d
Number of subjects: 0
Study 616841087 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g fiber from SCF/d
Number of subjects: 0
Study 35065291 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free pain management pathway (OF)
Number of subjects: 67
Study 35065291 — intervention group
Group type: COMPARATOR
Intervention: Traditional opioid-containing pain management pathway (OC)
Number of subjects: 67
Study 34635058 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic dermatitis group (experimental group)
Number of subjects: 61
Study 34635058 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-atopic patients)
Number of subjects: 61
Study 32273542 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of consumption of sugary drinks
Number of subjects: 1370
Study 32273542 — intervention group
Group type: EXPERIMENTAL
Intervention: Season of birth
Number of subjects: 1370
Study 32273542 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 1370
Study 32273542 — intervention group
Group type: EXPERIMENTAL
Intervention: Place of residence
Number of subjects: 1370
Study 32273542 — intervention group
Group type: EXPERIMENTAL
Intervention: Father's educational level
Number of subjects: 1370
Study 32273542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's educational level
Number of subjects: 1370
Study 32273542 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of housing
Number of subjects: 1370
Study 32273542 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoking at home
Number of subjects: 1370
Study 32273542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping hours during weekends
Number of subjects: 1370
Study 32273542 — intervention group
Group type: EXPERIMENTAL
Intervention: Students' educational level
Number of subjects: 1370
Study 35247729 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback-guided kinesthetic motor imagery training (MI-NF)
Number of subjects: 44
Study 35247729 — intervention group
Group type: COMPARATOR
Intervention: Active control visual imagery (VI)
Number of subjects: 44
Study 34719909 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with portable magnet therapy device ALMAG+ (Almag Active)
Number of subjects: 77
Study 34719909 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 77
Study 32925287 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 458
Study 32925287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 36350354 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-informed precision dosing (MIPD) of beta-lactam antibiotics and ciprofloxacin
Number of subjects: 388
Study 36350354 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of beta-lactam antibiotics and ciprofloxacin
Number of subjects: 388
Study 33175638 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic information with additional detail about timeline of HPV infection (Group 2)
Number of subjects: 585
Study 33175638 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic information with a diagram (Group 3)
Number of subjects: 585
Study 33175638 — intervention group
Group type: COMPARATOR
Intervention: Basic information (Group 1)
Number of subjects: 585
Study 34566873 — intervention group
Group type: EXPERIMENTAL
Intervention: Active FGMS
Number of subjects: 34
Study 34566873 — intervention group
Group type: COMPARATOR
Intervention: Sham FGMS
Number of subjects: 34
Study 34003436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration < 6 hours
Number of subjects: 505
Study 34003436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration 6-7 hours
Number of subjects: 505
Study 34003436 — intervention group
Group type: EXPERIMENTAL
Intervention: > 7 hours of sleep
Number of subjects: 505
Study 33766423 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational follow-up with the motivational interview technique (phone calls during weeks 1, 3, 6, and 9)
Number of subjects: 80
Study 32874115 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dye Taping
Number of subjects: 15
Study 32874115 — intervention group
Group type: COMPARATOR
Intervention: Sham Taping
Number of subjects: 15
Study 32874115 — intervention group
Group type: EXPERIMENTAL
Intervention: Running Speed Increase
Number of subjects: 15
Study 35143022 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on predictive model
Number of subjects: 49750
Study 35143022 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk groups derived from risk score
Number of subjects: 49750
Study 35143022 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline comorbidities and treatments
Number of subjects: 49750
Study 35143022 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu vaccination
Number of subjects: 49750
Study 35143022 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs increasing risk
Number of subjects: 49750
Study 33711985 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-peer teaching (NPT) tutor assistance
Number of subjects: 60
Study 33711985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NPT tutor)
Number of subjects: 60
Study 32399253 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI)
Number of subjects: 270
Study 32399253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 32399253 — intervention group
Group type: EXPERIMENTAL
Intervention: RCI
Number of subjects: 270
Study 35655225 — intervention group
Group type: EXPERIMENTAL
Intervention: Jian-Pi Huo-Xue granule (JPHX)
Number of subjects: 84
Study 35655225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 35655225 — intervention group
Group type: EXPERIMENTAL
Intervention: JPHX
Number of subjects: 84
Study 33301017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 50 mg every 6 hours for 5 to 7 days
Number of subjects: 2548
Study 33301017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 50 mg every 6 hours for 5 to 7 days with enteral 50 μg of fludrocortisone daily for 7 days
Number of subjects: 2548
Study 33301017 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat by SAPS II strategy
Number of subjects: 2548
Study 33301017 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal individual model strategy
Number of subjects: 2548
Study 33301017 — intervention group
Group type: COMPARATOR
Intervention: Placebo or usual care
Number of subjects: 2548
Study 36449096 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine (1000 mg capsule three times a day for 1 month)
Number of subjects: 76
Study 36449096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 34039574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental nursing care protocol
Number of subjects: 840
Study 34039574 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 840
Study 33160382 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (5 × 1 min at 80–95% maximal heart rate on cycle ergometers, 2×/week for 12 weeks)
Number of subjects: 65
Study 33160382 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 65
Study 33160382 — intervention group
Group type: COMPARATOR
Intervention: CON (inactive control group)
Number of subjects: 65
Study 35946487 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-initiated kangaroo mother care (ciKMC)
Number of subjects: 550
Study 34157093 — intervention group
Group type: EXPERIMENTAL
Intervention: omidubicel
Number of subjects: 125
Study 34157093 — intervention group
Group type: COMPARATOR
Intervention: standard UCBT
Number of subjects: 125
Study 32668408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 15
Study 32668408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 15
Study 33455931 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-enabled rehabilitation package (exercise program via Physitrack app, health-coaching via video calls, physical activity tracker with goal setting, Goniometer app for TKR)
Number of subjects: 204
Study 33455931 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-enabled rehabilitation package
Number of subjects: 204
Study 33455931 — intervention group
Group type: COMPARATOR
Intervention: Usual postsurgical care
Number of subjects: 204
Study 32085716 — intervention group
Group type: EXPERIMENTAL
Intervention: Atmiyata intervention (community-based interventions for mental health, including evidence-based counseling)
Number of subjects: 1520000
Study 32085716 — intervention group
Group type: EXPERIMENTAL
Intervention: Atmiyata intervention
Number of subjects: 1520000
Study 32357128 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based McKenzie therapy (TBMT)
Number of subjects: 47
Study 32357128 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based McKenzie therapy (CBMT)
Number of subjects: 47
Study 36203394 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapy (NRT) patches, 5-week supply provided to half of the participants.
Number of subjects: 0
Study 36203394 — intervention group
Group type: COMPARATOR
Intervention: NRT patches
Number of subjects: 0
Study 32918306 — intervention group
Group type: COMPARATOR
Intervention: Biopsy A (no SWE guidance)
Number of subjects: 58
Study 32918306 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy B (SWE guidance, rigid areas)
Number of subjects: 58
Study 32918306 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy C (SWE guidance, less rigid areas)
Number of subjects: 58
Study 35748897 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost
Number of subjects: 298
Study 35748897 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM
Number of subjects: 298
Study 35748897 — intervention group
Group type: COMPARATOR
Intervention: DT
Number of subjects: 298
Study 35748897 — intervention group
Group type: COMPARATOR
Intervention: Radiologists
Number of subjects: 298
Study 33591324 — intervention group
Group type: EXPERIMENTAL
Intervention: RW-CHOP (CHOP-21 with 8 doses of weekly rituximab [375 mg/m2])
Number of subjects: 421
Study 33591324 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (CHOP-21 with 8 doses of rituximab once every 3 weeks [375 mg/m2])
Number of subjects: 421
Study 32379236 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR WIDE
Number of subjects: 14
Study 32379236 — intervention group
Group type: COMPARATOR
Intervention: NO-BFR
Number of subjects: 14
Study 33034180 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-gradient therapy combined with orthodontic correction (n=29)
Number of subjects: 57
Study 33034180 — intervention group
Group type: COMPARATOR
Intervention: Orthodontic correction alone (n=28)
Number of subjects: 57
Study 35904769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypochlorous acid (HClO)
Number of subjects: 75
Study 35904769 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone‐iodine (PVP‐I)
Number of subjects: 75
Study 35904769 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 75
Study 33887962 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week movement skill intervention
Number of subjects: 0
Study 32847916 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive balance training (RBT) - one session
Number of subjects: 36
Study 32847916 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive balance training (RBT) - three sessions
Number of subjects: 36
Study 32847916 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive balance training (RBT) - six sessions
Number of subjects: 36
Study 32847916 — intervention group
Group type: COMPARATOR
Intervention: Regular physiotherapy (control)
Number of subjects: 36
Study 32847916 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls and physical activity reporting
Number of subjects: 36
Study 35106620 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg at bedtime
Number of subjects: 28
Study 35106620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 34283647 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 9 Gy SBRT regimen
Number of subjects: 20
Study 34152878 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational forgiveness intervention
Number of subjects: 21
Study 34152878 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education grief intervention with a humanistic approach
Number of subjects: 21
Study 33093338 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT Teens
Number of subjects: 40
Study 33093338 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 40
Study 34971381 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced implementation condition (with added patient tracking features and more implementation strategies)
Number of subjects: 14
Study 34971381 — intervention group
Group type: COMPARATOR
Intervention: Basic implementation condition (standard implementation)
Number of subjects: 14
Study 34971381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (Enhanced and Basic)
Number of subjects: 14
Study 34326048 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% tea tree oil (TTO) gel
Number of subjects: 88
Study 34326048 — intervention group
Group type: COMPARATOR
Intervention: 0.05% potassium permanganate (KMnO4) solution
Number of subjects: 88
Study 32729405 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress situation (Trier Social Stress Test)
Number of subjects: 47
Study 32729405 — intervention group
Group type: COMPARATOR
Intervention: Neutral control task
Number of subjects: 47
Study 35227369 — intervention group
Group type: EXPERIMENTAL
Intervention: Household chaos (HHchaos)
Number of subjects: 105
Study 33122343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 11
Study 33122343 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 11
Study 33122343 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 11
Study 33122343 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab and Pertuzumab (combined)
Number of subjects: 11
Study 33122343 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant anti-HER2 therapy
Number of subjects: 11
Study 35140313 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU of vitamin D3 taken daily
Number of subjects: 2423
Study 35140313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2423
Study 34494901 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging reconstruction using dermal allograft
Number of subjects: 30
Study 34494901 — intervention group
Group type: COMPARATOR
Intervention: Maximal repair
Number of subjects: 30
Study 36093886 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of 12 cmH2O with hourly ARMs (n=83)
Number of subjects: 162
Study 36093886 — intervention group
Group type: COMPARATOR
Intervention: PEEP of 4 cmH2O (n=79)
Number of subjects: 162
Study 35010394 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 17
Study 35010394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 34599139 — intervention group
Group type: EXPERIMENTAL
Intervention: venetoclax +LDAC
Number of subjects: 211
Study 34599139 — intervention group
Group type: COMPARATOR
Intervention: placebo +LDAC
Number of subjects: 211
Study 33393275 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional adhesive Maryland‐bridge (AMB) applied for 3 months
Number of subjects: 18
Study 33393275 — intervention group
Group type: COMPARATOR
Intervention: No AMB (Control group)
Number of subjects: 18
Study 33393275 — intervention group
Group type: EXPERIMENTAL
Intervention: AMB
Number of subjects: 18